OSU-2S
Based on 1 publication(s) in Google Scholar
OSU-2S is a potent PKCδ activator. OSU-2S inhibits cell proliferation and migration. OSU-2S decreases the expression of p-ERK1/2, increases the expression of PKCδ (38 kDa) when combined with Sorafenib (HY-10201). OSU-2S induces Apoptosis. OSU-2S slao is a non-immunosuppressive analogue of FTY720. OSU-2S shows anticancer activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1351056-65-9
- Formule: C21H37NO2
- Masse moléculaire:335.52
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) OSU-2S
More
Activité biologique
Description
IC50 & Target
[1]|
PKCδ |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
4.2 μM
Compound: OSU-2S
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
| Hep 3B2 | IC50 |
2.8 μM
Compound: OSU-2S
|
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
| HepG2 | IC50 |
2.3 μM
Compound: OSU-2S
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
| HT-29 | IC50 |
2.7 μM
Compound: OSU-2S
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
In Vitro
OSU-2S (1.25, 2.5 µM; 48 h) decreases the expression of p-ERK1/2, increases the expression of PKCδ (38 kDa) when combined with Sorafenib (HY-10201) (2.5, 5 µM)[1].
OSU-2S/Sorafenib (1.25, 2.5 µM; 8 h) combinantion inhibits cell proliferative and migration[1].
OSU-2S (0, 1, 2.5, 5 µM; 0-24 h) decreases the expression of PARP in a dose and time-dependent manner in Hep3B cells[2].
OSU-2S (5 µM; 12, 24 h) induces apoptosis in Hep3B cells[2].
OSU-2S (0-10 µM; 1 h) stimulates ROS production in a dose-dependent manner in Hep3B, Huh7, PLC-5 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Hep3B, Huh7, PLC-5, HepG2 cells
-
Concentration:0-10 µM
-
Incubation Time:48 h
-
Result:Showed anti-proliferative effects with IC50s of 2.53, 2.41, 3.96, 1.84 µM for Hep3B, Huh7, PLC-5, HepG2 cells, respectively.
-
Cell Line:Hep3B cells
-
Concentration:1.25, 2.5 µM combinated with sorafenib (2.5, 5 µM)
-
Incubation Time:48 h
-
Result:Decreased the expression of ERK1/2 phosphorylation, increased the expression of PKCδ (38 kDa) when sorafenib/OSU-2S combination.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD2F1 mice (Hep3B tumor xenograft models)[2]
-
Dosage:5, 10 mg/kg
-
Administration:I.p.; once daily for 42 days
-
Result:Exhibited a higher tumor-suppressive potency, achieving 80% reduction in bioluminescence at the end of treatment.
Chemical Information
-
CAS No. 1351056-65-9
-
Masse moléculaire 335.52
-
Formule C21H37NO2
-
SMILES
CCC[C@@](CCC1=CC=C(OCCCCCC(C)C)C=C1)(N)CO
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Osthole alleviates neuropathic pain by suppressing astrocytes activation and associated inflammatory responses via the PKCδ/TRPV4 signaling pathway. [Abstract]2025 Sep 10:165:115453. PMID: 40934539
Pureté et documentation
Références
[1]. Omar HA, et al. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53. Front Pharmacol. 2016 Nov 30;7:463. [Content Brief]
[2]. Omar HA, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology. 2011 Jun;53(6):1943-58. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
OSU-2S Related Classifications
HY-117720 Related Classifications
Powered by Bioz